<?xml version='1.0' encoding='utf-8'?>
<document id="30203386"><sentence text="Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects."><entity charOffset="77-88" id="DDI-PubMed.30203386.s1.e0" text="Oseltamivir" /></sentence><sentence text="Baloxavir marboxil is a prodrug that is metabolized to baloxavir acid, which suppresses viral replication by inhibiting cap-dependent endonuclease with a single oral administration"><entity charOffset="0-18" id="DDI-PubMed.30203386.s2.e0" text="Baloxavir marboxil" /><entity charOffset="55-69" id="DDI-PubMed.30203386.s2.e1" text="baloxavir acid" /><pair ddi="false" e1="DDI-PubMed.30203386.s2.e0" e2="DDI-PubMed.30203386.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30203386.s2.e0" e2="DDI-PubMed.30203386.s2.e1" /></sentence><sentence text=" As the mode of action of baloxavir marboxil is different from that of neuraminidase inhibitors, such as oseltamivir, combination treatment with these drugs can be a treatment option, particularly for severe influenza infection"><entity charOffset="26-44" id="DDI-PubMed.30203386.s3.e0" text="baloxavir marboxil" /><entity charOffset="105-116" id="DDI-PubMed.30203386.s3.e1" text="oseltamivir" /><pair ddi="false" e1="DDI-PubMed.30203386.s3.e0" e2="DDI-PubMed.30203386.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30203386.s3.e0" e2="DDI-PubMed.30203386.s3.e1" /></sentence><sentence text=" The aim of this study was to assess the drug-drug interaction between baloxavir marboxil and oseltamivir"><entity charOffset="94-105" id="DDI-PubMed.30203386.s4.e0" text="oseltamivir" /></sentence><sentence text="" /><sentence text="Eighteen healthy adult subjects received three treatments in a crossover fashion: single administration of baloxavir marboxil 40 mg alone, repeated twice-daily administration of oseltamivir at 75 mg for 5 days, or single administration of baloxavir marboxil at 40 mg in combination with repeated twice-daily administration of oseltamivir at 75 mg for 5 days"><entity charOffset="178-189" id="DDI-PubMed.30203386.s6.e0" text="oseltamivir" /><entity charOffset="239-257" id="DDI-PubMed.30203386.s6.e1" text="baloxavir marboxil" /><entity charOffset="326-337" id="DDI-PubMed.30203386.s6.e2" text="oseltamivir" /><pair ddi="false" e1="DDI-PubMed.30203386.s6.e0" e2="DDI-PubMed.30203386.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30203386.s6.e0" e2="DDI-PubMed.30203386.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30203386.s6.e0" e2="DDI-PubMed.30203386.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30203386.s6.e1" e2="DDI-PubMed.30203386.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30203386.s6.e1" e2="DDI-PubMed.30203386.s6.e2" /></sentence><sentence text="" /><sentence text="The ratios (90% confidence intervals) of maximum plasma concentration and area under the plasma concentration-time curve of baloxavir acid after co-administration compared to baloxavir marboxil alone were 1"><entity charOffset="124-138" id="DDI-PubMed.30203386.s8.e0" text="baloxavir acid" /></sentence><sentence text="03 (0" /><sentence text="92-1" /><sentence text="15) and 1" /><sentence text="01 (0" /><sentence text="96-1" /><sentence text="06), respectively" /><sentence text=" The ratios (90% confidence intervals) of maximum plasma concentration and area under the plasma concentration-time curve of oseltamivir carboxylate, the active form of oseltamivir, after co-administration compared to oseltamivir alone were 0"><entity charOffset="125-148" id="DDI-PubMed.30203386.s15.e0" text="oseltamivir carboxylate" /><entity charOffset="169-180" id="DDI-PubMed.30203386.s15.e1" text="oseltamivir" /><entity charOffset="218-229" id="DDI-PubMed.30203386.s15.e2" text="oseltamivir" /><pair ddi="false" e1="DDI-PubMed.30203386.s15.e0" e2="DDI-PubMed.30203386.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30203386.s15.e0" e2="DDI-PubMed.30203386.s15.e1" /><pair ddi="false" e1="DDI-PubMed.30203386.s15.e0" e2="DDI-PubMed.30203386.s15.e2" /><pair ddi="false" e1="DDI-PubMed.30203386.s15.e1" e2="DDI-PubMed.30203386.s15.e1" /><pair ddi="false" e1="DDI-PubMed.30203386.s15.e1" e2="DDI-PubMed.30203386.s15.e2" /></sentence><sentence text="96 (0" /><sentence text="93-1" /><sentence text="00) and 0" /><sentence text="99 (0" /><sentence text="96-1" /><sentence text="01), respectively, at steady state on day 5" /><sentence text=" Treatment-emergent adverse events reported were mild and not considered to be related to the study drug" /><sentence text="" /><sentence text="The lack of a clinically meaningful drug-drug interaction between baloxavir marboxil and oseltamivir has been established"><entity charOffset="89-100" id="DDI-PubMed.30203386.s24.e0" text="oseltamivir" /></sentence><sentence text="" /></document>